SOS1
SOS1 (Son of sevenless homolog 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Skin cancer, Breast cancer and 1 more.
Overview
Promotes the exchange of Ras-bound GDP by GTP. Probably by promoting Ras activation, regulates phosphorylation of MAP kinase MAPK3/ERK1 in response to EGF. Catalytic component of a trimeric complex that participates in transduction of signals from Ras to Rac by promoting the Rac-specific guanine nucleotide exchange factor (GEF) activity.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.80 (direct and indirect evidence; datatypes affected pathway 0.83, literature 0.94, genetic association 0.00, somatic mutation 0.91, animal model 0.38). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Endometrial Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · SOS1 (Son of sevenless homolog 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Skin cancer, Breast cancer and 1 more.
- 1 · What it is
SOS1 (Son of sevenless homolog 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Skin cancer, Breast cancer and 1 more.
- 2 · What goes wrong in cancer
Promotes the exchange of Ras-bound GDP by GTP. Probably by promoting Ras activation, regulates phosphorylation of MAP kinase MAPK3/ERK1 in response to EGF.
- 3 · How drugs use it
No product in this corpus aims at SOS1 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:11187 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q07889 (protein name, function text, keywords and locations (REST API)); CIViC gene SOS1 (1 evidence items, 0 assertions, 1 variants; diseases: (GraphQL API, CC0)); Open Targets ENSG00000115904 (association with cancer (MONDO_0004992) 0.80; per-cancer scores at or above 0.5: gastric cancer 0.51, endometrial cancer 0.53, skin cancer 0.56, breast cancer 0.53 (GraphQL API, CC0)); IntOGen SOS1 (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Promotes the exchange of Ras-bound GDP by GTP. Probably by promoting Ras activation, regulates phosphorylation of MAP kinase MAPK3/ERK1 in response to EGF. Catalytic component of a trimeric complex that participates in transduction of signals from Ras to Rac by promoting the Rac-specific guanine nucleotide exchange factor (GEF) activity. Locus 2p22.1 (HGNC).
- Endometrial cancer: Open Targets association 0.53 with endometrial cancer (MONDO_0011962); IntOGen driver in 1 cohort (UCEC)
- Skin cancer: Open Targets association 0.56 with skin cancer (MONDO_0002898)
- Breast cancer: Open Targets association 0.53 with breast cancer (MONDO_0007254)
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.51 with gastric cancer (MONDO_0001056)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"SOS1" OR ABSTRACT:"SOS1" OR TITLE:"SOS Ras/Rac guanine nucleotide exchange factor 1" OR ABSTRACT:"SOS Ras/Rac guanine nucleotide exchange factor 1" OR TITLE:"Son of sevenless homolog 1" OR ABSTRACT:"Son of sevenless homolog 1" OR TITLE:"GF1" OR ABSTRACT:"GF1" OR TITLE:"GINGF" OR ABSTRACT:"GINGF") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SOS1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetMAPK3
- TargetMYC
Shares RAS / RAF / MEK / ERK (MAPK), Skin cancer (all types), Breast cancer (all types), CIViC.
- CompanyQuanta Therapeutics
- TreatmentBemarituzumab
Shares RAS / RAF / MEK / ERK (MAPK), Gastric & gastro-oesophageal junction cancer.
- TargetGRB2
- PathwayEndometrial cancer (KEGG map)
- PathwayFGF / FGFR signalling
Shares RAS / RAF / MEK / ERK (MAPK), Gastric & gastro-oesophageal junction cancer.